Market Place
Sourcing Support
Texas biotech axes cancer pact, pins hopes on obesity
11 Oct 2024 //
FIERCE BIOTECH
Precigen to Participate in the 2024 Cantor Global Healthcare Conference
16 Sep 2024 //
PR NEWSWIRE
Precigen To Announce Q2 And H1 2024 Results On August 14
09 Aug 2024 //
PR NEWSWIRE
Precigen Cuts 20% Staff, Pauses Programs To Fund Approval Filing
07 Aug 2024 //
FIERCE BIOTECH
Precigen Announces Pricing of $30.0 Million Public Offering of Common Stock
07 Aug 2024 //
PR NEWSWIRE
Precigen Prioritizes Portfolio For First Potential Gene Therapy Launch
06 Aug 2024 //
PR NEWSWIRE
Precigen`s PRGN-2012 Shows Over 50% Complete Response In RRP
03 Jun 2024 //
PR NEWSWIRE
Precigen Prgn-2012 Papillomatosis: Pivotal Study Results Webcast Asco24
23 May 2024 //
PR NEWSWIRE
Precigen Reports First Quarter 2024 Financial Results and Business Updates
14 May 2024 //
PR NEWSWIRE
Precigen: Q1 2024 Financial Results Announcement and Conference Call
08 May 2024 //
PR NEWSWIRE
Precigen`s RRP Immunotherapy PRGN-2012 Data at ASCO 2024
24 Apr 2024 //
PR NEWSWIRE
Precigen Reports Full Year 2023 Financial Results and Business Updates
19 Mar 2024 //
PR NEWSWIRE
Precigen Receives Orphan Drug Designation for PRGN-2012
16 Jan 2024 //
PR NEWSWIRE
Precigen Highlights Pipeline Updates to be Presented
08 Jan 2024 //
PR NEWSWIRE
Precigen Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
Precigen to Participate in the Stifel 2023 Healthcare Conference
07 Nov 2023 //
PR NEWSWIRE
Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse
20 Jun 2023 //
PR NEWSWIRE
ASCO 2023: Precigen reports positive early data for CAR-T therapy
06 Jun 2023 //
CLINICAL TRIALS ARENA
Precigen Announces Positive Phase 1 Data for PRGN-3005
05 Jun 2023 //
PR NEWSWIRE
Precigen Announces PI Data for Off-the-Shelf PRGN-2009 AdenoVerse Immunotherapy
03 Jun 2023 //
PR NEWSWIRE
Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009
31 May 2023 //
PR NEWSWIRE
Precigen Reports First Quarter 2023 Financial Results and Business Updates
10 May 2023 //
PR NEWSWIRE
Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T
17 Apr 2023 //
PR NEWSWIRE
Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19/BCMA
04 Apr 2023 //
CONTRACT PHARMA
Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA
03 Apr 2023 //
PR NEWSWIRE
Precigen Announces Advancement of UltraCAR-T Platform
29 Mar 2023 //
PR NEWSWIRE
Precigen to Participate in Fireside Chat at "The Future of Oncology" Symposium
28 Mar 2023 //
PR NEWSWIRE
Precigen Reports Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
PR NEWSWIRE
Precigen to Share Efficacy Data from PI Expansion Cohorts of PRGN-2012
04 Jan 2023 //
PR NEWSWIRE
Precigen Announces PI Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T
12 Dec 2022 //
PRNEWSWIRE
Precigen Names Rutul R. Shah Chief Operating Officer
21 Sep 2022 //
PRNEWSWIRE
Precigen Reports Second Quarter and First Half 2022 Financial Results
08 Aug 2022 //
PRNEWSWIRE
Precigen Receives FTD for PRGN-3006 UltraCAR-T in r/r AML
04 Apr 2022 //
PRNEWSWIRE
Precigen Provides Pipeline and Corporate Updates at JPM 2022
12 Jan 2022 //
PRNEWSWIRE
Precigen Achieves Significant Clinical Progress for UltraCAR-T®
04 Nov 2021 //
PRNEWSWIRE
Precigen Achieves Significant Clinical Progress for UltraCAR-T
04 Nov 2021 //
FIRSTWORDPHARMA
Precigen to Host R&D Update Virtual Event to Share Clinical Developments
27 Oct 2021 //
PRNEWSWIRE
Precigen to Announce Second Quarter and First Half 2021 Financial Results
02 Aug 2021 //
PRNEWSWIRE
Precigen Announces First Patient Dosed for PRGN-2012 AdenoVerse™ Immunotherapy
23 Mar 2021 //
PRNEWSWIRE
US FDA grants orphan drug status to Precigen’s PRGN-2012 AdenoVerse
19 Mar 2021 //
PHARMABIZ
Precigen Receives FDA Orphan Drug Designation for PRGN-2012 AdenoVerse
18 Mar 2021 //
PRNEWSWIRE
Precigen Announces Pricing of $112.5 Million Public Offering of Common Stock
22 Jan 2021 //
PRNEWSWIRE
Precigen Provides Pipeline Updates at the 39th Annual J.P. Morgan
13 Jan 2021 //
PRNEWSWIRE
Precigen Announces Clearance of IND to Initiate Ph I Study of PRGN-2012
05 Jan 2021 //
PRNEWSWIRE
Precigen Provides Latest Clinical Developments at Virtual R&D Update Event
15 Dec 2020 //
PRNEWSWIRE
Precigen Presents New Data Supporting the Safety, of PRGN-3006
07 Dec 2020 //
PRNEWSWIRE
Precigen Announces Dosing of First Patients with UltraCAR-T® Cells Manufactured
16 Nov 2020 //
PRNEWSWIRE
Stock Alert: Precigen Climbs 20% As Merck Increases Stake In The Co.
09 Oct 2020 //
NASDAQ
Precigen Announces First Patient Dosed in Phase I/II Study PRGN-2009
17 Aug 2020 //
PRNEWSWIRE
Preclinical Data for PRGN-3005 UltraCAR-T® Demonstrate Superior Expansion
22 Jun 2020 //
PRNEWSWIRE
Precigen to Present Preclinical Data for PRGN-3005 UltraCAR-T™
15 May 2020 //
PRNEWSWIRE
Precigen Announces of IND to Initiate Ph I/II Study for First-in-Class PRGN-2009
20 Apr 2020 //
PR NEWSWIRE
